Why This Isn't a Typical Pharmacy Prior Auth
If you've read a prior authorization guide for a drug like Ozempic or Cosentyx, you've seen the pattern: a pharmacy rejects the claim, the prescriber's office logs into CoverMyMeds, a plan-specific form gets filled out, and a specialty pharmacy eventually ships the medication. Keytruda mostly skips that entire pathway.
Keytruda (pembrolizumab) is given as an intravenous infusion in an oncologist's office, an infusion center, or a hospital outpatient department. Drugs administered this way are almost always billed under a health plan's medical benefit — the same benefit that covers a surgery or an MRI — rather than the pharmacy benefit that covers a bottle of pills picked up at a counter. That single distinction changes almost everything about how the prior authorization gets handled.
| Typical retail/specialty pharmacy drug | Keytruda (medical benefit) | |
|---|---|---|
| Who files the PA | Prescriber's office, via the pharmacy | Oncology practice's PA/financial counseling staff |
| Where it's submitted | CoverMyMeds, Surescripts, or a PBM portal | The health plan's medical UM portal, or a delegated oncology benefit manager's portal |
| Who dispenses it | Retail or specialty pharmacy | The infusing practice itself buys and bills the drug ("buy and bill") |
| Billing code type | NDC, processed as a pharmacy claim | HCPCS J-code, processed as a medical claim |
| Clinical criteria source | Plan formulary + step therapy rules | Plan medical policy, often built on NCCN Compendium listings |
This is also why calling a number printed on a "prior authorization required" guide for retail drugs, or a PBM's member-services line, tends to go nowhere for a Keytruda question. The people who can actually tell you the status of the request are the oncology practice's PA coordinator and the health plan's medical management department — not a pharmacy help desk.
One exception worth knowing about: under some Medicare Part D plans, and in a smaller number of commercial plans, an oral oncology-adjacent medication tied to your treatment (for example, an anti-nausea drug or an oral targeted therapy given alongside pembrolizumab) can still route through the pharmacy benefit and require its own separate PA. Keytruda itself, though, virtually never does.
Who Actually Reviews the Request
For a medical-benefit drug like Keytruda, the reviewer isn't a pharmacist checking a formulary list — it's typically a nurse reviewer or medical director evaluating the request against the plan's oncology drug policy. Because Keytruda carries dozens of separate FDA-approved indications, each with its own eligibility language, that policy has to account for which cancer type, stage, and biomarker profile the request is for.
Medicare has a specific rule that shapes this review for off-label or edge-case anti-cancer drug use: coverage determinations for cancer drugs are allowed to rely on medical evidence found in CMS-recognized drug compendia, including the NCCN Drugs & Biologics Compendium. In practice, this means a reviewer isn't only checking the FDA label — they're also checking whether NCCN guidelines support the specific regimen being requested, which matters most when a request falls outside the exact label language (for example, a combination regimen or a less common tumor type).
| Indication category | Typical biomarker/testing evidence requested |
|---|---|
| Non-small cell lung cancer | PD-L1 expression (TPS), histology, prior systemic therapy if applicable |
| Head and neck squamous cell carcinoma | PD-L1 Combined Positive Score (CPS) |
| Tumor-agnostic (any solid tumor) | MSI-H/dMMR or TMB-H status, prior treatment options exhausted |
| Urothelial carcinoma | Disease stage, prior platinum-based therapy or cisplatin ineligibility |
| Classical Hodgkin lymphoma | Prior treatment line, relapsed/refractory status |
Many payers don't keep this review in-house at all. Oncology and other high-cost specialty drug categories are frequently delegated to a specialty benefit management company under contract with the insurer — most commonly EviCore by Evernorth or Carelon Medical Benefits Management — which conducts the clinical review and issues the determination on the plan's behalf. If your explanation of benefits or a denial letter references a company you don't recognize, this delegation is usually why. The decision still carries the same coverage and appeal rights as one made directly by your insurer.
How the Process Moves, Step by Step
1. Diagnosis & staging confirmed
Oncologist orders biomarker testing relevant to the specific indication (e.g., PD-L1, MSI-H/dMMR)
2. Benefits investigation
Practice's PA staff confirms whether medical benefit PA is required and which entity reviews it (plan itself, or a delegated vendor)
3. Request submitted
Through the payer's or vendor's medical UM portal, with diagnosis, staging, biomarker results, and treatment plan attached
4. Clinical review
Nurse reviewer or medical director checks the request against plan medical policy and, where relevant, NCCN Compendium listings
5. Decision & scheduling
If approved, infusion is scheduled. Approval is usually for a defined number of cycles or a fixed period, not indefinite
That last point trips people up: an approval isn't necessarily a one-time event that covers the entire course of treatment. Plans commonly authorize an initial block of cycles, then require the oncology practice to submit a reauthorization with updated scan or response data to continue coverage — which is one reason Keytruda infusions can occasionally get held up mid-treatment even after the first cycles were already approved and paid.
What Documentation Keytruda Requests Usually Need
- Confirmed diagnosis with staging — pathology report and staging that matches an FDA-approved (or NCCN-supported) indication for pembrolizumab.
- Biomarker testing results relevant to that specific indication — not every Keytruda indication requires the same biomarker, so the wrong test attached is a common paperwork gap.
- Treatment history — prior systemic therapies tried, and outcomes, particularly for indications where Keytruda is approved after progression on other treatment rather than as a first-line option.
- Planned regimen and dosing — whether Keytruda is being given alone or in combination with chemotherapy, and the intended schedule (commonly every 3 weeks or every 6 weeks, depending on the regimen).
- Site of service — where the infusion will take place, since some plans apply site-of-care policies that prefer lower-cost outpatient or in-office settings over hospital-based infusion when clinically appropriate.
Keytruda Qlex and the 2026 Coding Wrinkle
In September 2025, the FDA approved Keytruda Qlex (pembrolizumab and berahyaluronidase alfa-pmph), a subcutaneous injection version of pembrolizumab that can be given by a healthcare provider in as little as one to two minutes, instead of the roughly 30-minute IV infusion required for standard Keytruda. It's approved across the same broad set of solid tumor indications as IV Keytruda, for patients 12 and older.
For prior authorization purposes, the important detail is that Keytruda Qlex is a separate, distinct product from IV Keytruda — it has its own FDA approval and its own billing code, not a repurposed version of the existing one. Because it's still a relatively new product as of this update, some health plans may not yet have finished building a dedicated coverage policy for it, or may not have added it to their preferred-agent lists in the same position as IV Keytruda.
What this means in practice: if your oncology practice is considering switching a patient from IV Keytruda to Keytruda Qlex — or starting a new patient on the subcutaneous version — it's worth confirming with the plan whether that specific product already has a coverage determination on file, rather than assuming the existing IV authorization automatically carries over. This is a newer wrinkle that most general prior-authorization content published before late 2025 won't mention at all.
How Long a Decision Actually Takes, By Plan Type
This is where a lot of otherwise-good prior authorization content gets Keytruda wrong, because it applies a rule that was written for a different category of request.
| Plan type | Standard request | Expedited/urgent request |
|---|---|---|
| Medicare Advantage (Part B drug) | 72 hours — cannot be extended | 24 hours |
| Medicare Advantage — appeal (reconsideration) of a Part B drug denial | 7 calendar days | 72 hours |
| Commercial/employer-sponsored plans (ERISA) | Generally around 15 calendar days, one extension possible with notice | Generally around 72 hours |
| Medicaid managed care / CHIP / ACA marketplace | Varies by state and plan; check the plan's Evidence of Coverage | Varies by state and plan |
The Medicare Advantage figures above come directly from federal regulation, not from CMS-0057-F. Under 42 CFR § 422.568, a request for a Part B drug — which is what Keytruda is — must be decided within 72 hours of receipt, and unlike most other standard organization determinations, that window cannot be extended. Expedited Part B drug requests get an even tighter 24-hour window under 42 CFR § 422.572. These rules have been in place since 2020, well before CMS-0057-F existed.
CMS-0057-F, the rule that took operational effect on January 1, 2026 and introduced the widely quoted "7 days standard / 72 hours expedited" language, applies to non-drug items and services — imaging, procedures, durable medical equipment, and similar requests. CMS has stated plainly that it excluded drugs from this rule because drug prior authorization "differs from" the process for medical items and services, and that it may address drugs in future rulemaking (a related proposal, CMS-0062-P, was released in April 2026 and would extend similar requirements to drugs starting around October 2027, though as of this update it remains a proposed rule, not yet final).
The practical upshot: if your oncology practice's Keytruda request to a Medicare Advantage plan is sitting past 72 hours with no decision, you have a real, specific regulatory hook to escalate on — a call script that says "this is a Part B drug request under 422.568, which has already hit the 72-hour deadline" is more precise, and harder to brush off, than citing a 7-day CMS-0057-F window that doesn't actually govern drug requests at all.
Common Reasons Keytruda Requests Get Denied
| Reason | What's usually going on |
|---|---|
| Missing or mismatched biomarker documentation | The wrong test result was attached, or testing wasn't done for the specific indication being requested |
| Indication not clearly supported by the label or NCCN listing | The requested use falls outside FDA-approved language and the compendia support wasn't included in the submission |
| Non-preferred agent in a competitive therapeutic class | Some plans prefer a different PD-1/PD-L1 inhibitor as first-line and require documentation of why an alternative isn't appropriate |
| Treatment duration exceeds the plan's authorized period | Ongoing therapy beyond the initially approved number of cycles without a timely reauthorization submission |
| Site-of-care mismatch | Requested setting (e.g., hospital outpatient) doesn't match the plan's preferred lower-cost infusion setting for a clinically stable patient |
| New product, unclear policy | A request for Keytruda Qlex processed under criteria written only for the IV formulation, or vice versa |
Most of these are documentation and coding issues, not a plan simply refusing to cover Keytruda outright — pembrolizumab is FDA-approved and NCCN-supported for a wide range of cancers, so an outright non-coverage denial is comparatively unusual. When it happens, it's worth asking the reviewer specifically which piece of documentation, or which compendia listing, they say is missing, rather than resubmitting the identical request.
Appealing a Denial
The appeal path depends on the type of coverage:
- Medicare Advantage: the plan must reconsider a Part B drug denial within 7 calendar days for a standard appeal, or 72 hours for an expedited one. If the plan upholds its own denial, the case is automatically forwarded to an independent review entity for a fresh look — you don't have to separately request that step.
- Commercial/employer-sponsored plans: typically an internal appeal first, followed by the right to an independent external review through the state insurance department (or the federal external review process, depending on the plan) if the internal appeal is also denied.
- Medicaid managed care: appeal rights and timeframes are set at the state level, so the specific deadlines are in the plan's member handbook or Evidence of Coverage.
An appeal that specifically addresses the stated reason for denial — for example, attaching the missing biomarker report, or citing the specific NCCN Compendium listing that supports an off-label combination — is generally far more likely to succeed than one that simply resubmits the same paperwork with a cover letter asking for reconsideration.
Where Merck's Own Support Programs Fit In
Separate from the insurance decision itself, Merck operates support resources that can help a prescriber's office (and patients) navigate the process, though they don't control or override the plan's coverage determination:
- The Merck Access Program can assist with benefits investigations and can help a practice understand where a request stands in the prior authorization or appeal process.
- KEY+YOU, Merck's patient support program for people prescribed Keytruda, connects patients and caregivers to educational resources and can be reached at 855-398-7832 (dial 85-KEYTRUDA), option 2.
- The Merck Patient Assistance Program, a separate 501(c)(3) foundation, may provide Keytruda at no cost to eligible patients who are uninsured or underinsured and meet income requirements — this is a distinct program from insurance coverage and has its own application and enrollment forms, typically submitted through the prescriber's office.
None of these programs can force a health plan to approve a request. What they're generally useful for is taking some of the administrative load off the oncology practice's staff, and giving patients a fallback option if coverage genuinely isn't available.
Quick Checklist for the Oncology Office
| Checklist item | Status |
|---|---|
| Confirmed this is a medical-benefit (not pharmacy) prior authorization | ☐ |
| Identified whether the plan reviews in-house or delegates to a vendor (e.g., EviCore, Carelon) | ☐ |
| Attached biomarker testing that matches the specific requested indication | ☐ |
| Included staging, prior therapy history, and planned regimen/dosing | ☐ |
| Confirmed whether IV Keytruda or Keytruda Qlex has an active coverage policy with this plan | ☐ |
| Noted the correct regulatory deadline for follow-up (72 hours for MA Part B drug requests, not the general 7-day CMS-0057-F window) | ☐ |
| Saved a reference/case number after submission | ☐ |